Matches in DBpedia 2015-10 for { <http://dbpedia.org/resource/EGFR_inhibitors> ?p ?o }
Showing triples 1 to 43 of
43
with 100 triples per page.
- EGFR_inhibitors abstract "Many therapeutic approaches are aimed at epidermal growth factor receptor (EGFR). Cetuximab and panitumumab are examples of monoclonal antibody inhibitors. However the former is of the IgG1 type, the latter of the IgG2 type; consequences on antibody-dependent cellular cytotoxicity can be quite different. Other monoclonals in clinical development are zalutumumab, nimotuzumab, and matuzumab. The monoclonal antibodies block the extracellular ligand binding domain. With the binding site blocked, signal molecules can no longer attach there and activate the tyrosine kinase.Another method is using small molecules to inhibit the EGFR tyrosine kinase, which is on the cytoplasmic side of the receptor. Without kinase activity, EGFR is unable to activate itself, which is a prerequisite for binding of downstream adaptor proteins. Ostensibly by halting the signaling cascade in cells that rely on this pathway for growth, tumor proliferation and migration is diminished. Gefitinib, erlotinib, and lapatinib (mixed EGFR and ERBB2 inhibitor) are examples of small molecule kinase inhibitors.There are several quantitative methods available that use protein phosphorylation detection to identify EGFR family inhibitors.New drugs such as gefitinib and erlotinib directly target the EGFR. Patients have been divided into EGFR-positive and EGFR-negative, based upon whether a tissue test shows a mutation. EGFR-positive patients have shown a 60% response rate, which exceeds the response rate for conventional chemotherapy.However, many patients develop resistance. Two primary sources of resistance are the T790M Mutation and MET oncogene. However, as of 2010 there was no consensus of an accepted approach to combat resistance nor FDA approval of a specific combination. Preclinical results have been reported for AP26113 which targets the T790M mutation.The most common adverse effect of EGFR inhibitors, found in more than 90% of patients, is a papulopustular rash that spreads across the face and torso; the rash's presence is correlated with the drug's antitumor effect. In 10% to 15% of patients the effects can be serious and require treatment.".
- EGFR_inhibitors wikiPageID "42464222".
- EGFR_inhibitors wikiPageLength "4757".
- EGFR_inhibitors wikiPageOutDegree "22".
- EGFR_inhibitors wikiPageRevisionID "678362411".
- EGFR_inhibitors wikiPageWikiLink AP26113.
- EGFR_inhibitors wikiPageWikiLink Adverse_effect.
- EGFR_inhibitors wikiPageWikiLink Antibody-dependent_cell-mediated_cytotoxicity.
- EGFR_inhibitors wikiPageWikiLink Antibody-dependent_cellular_cytotoxicity.
- EGFR_inhibitors wikiPageWikiLink Brigatinib.
- EGFR_inhibitors wikiPageWikiLink Category:Targeted_therapy.
- EGFR_inhibitors wikiPageWikiLink Cetuximab.
- EGFR_inhibitors wikiPageWikiLink Enzyme_inhibitor.
- EGFR_inhibitors wikiPageWikiLink Epidermal_growth_factor_receptor.
- EGFR_inhibitors wikiPageWikiLink Erlotinib.
- EGFR_inhibitors wikiPageWikiLink Gefitinib.
- EGFR_inhibitors wikiPageWikiLink IgG1.
- EGFR_inhibitors wikiPageWikiLink IgG2.
- EGFR_inhibitors wikiPageWikiLink Immunoglobulin_G.
- EGFR_inhibitors wikiPageWikiLink Kinase.
- EGFR_inhibitors wikiPageWikiLink Lapatinib.
- EGFR_inhibitors wikiPageWikiLink Matuzumab.
- EGFR_inhibitors wikiPageWikiLink Monoclonal_antibodies.
- EGFR_inhibitors wikiPageWikiLink Monoclonal_antibody.
- EGFR_inhibitors wikiPageWikiLink Nimotuzumab.
- EGFR_inhibitors wikiPageWikiLink Panitumumab.
- EGFR_inhibitors wikiPageWikiLink Papulopustular.
- EGFR_inhibitors wikiPageWikiLink Rash.
- EGFR_inhibitors wikiPageWikiLink Zalutumumab.
- EGFR_inhibitors wikiPageWikiLinkText "EGFR inhibitors".
- EGFR_inhibitors wikiPageWikiLinkText "anti-EGFR therapies".
- EGFR_inhibitors hasPhotoCollection EGFR_inhibitors.
- EGFR_inhibitors wikiPageUsesTemplate Template:Context.
- EGFR_inhibitors wikiPageUsesTemplate Template:Multiple_issues.
- EGFR_inhibitors wikiPageUsesTemplate Template:Reflist.
- EGFR_inhibitors subject Category:Targeted_therapy.
- EGFR_inhibitors comment "Many therapeutic approaches are aimed at epidermal growth factor receptor (EGFR). Cetuximab and panitumumab are examples of monoclonal antibody inhibitors. However the former is of the IgG1 type, the latter of the IgG2 type; consequences on antibody-dependent cellular cytotoxicity can be quite different. Other monoclonals in clinical development are zalutumumab, nimotuzumab, and matuzumab. The monoclonal antibodies block the extracellular ligand binding domain.".
- EGFR_inhibitors label "EGFR inhibitors".
- EGFR_inhibitors sameAs m.0107zsnb.
- EGFR_inhibitors sameAs Q16966875.
- EGFR_inhibitors sameAs Q16966875.
- EGFR_inhibitors wasDerivedFrom EGFR_inhibitors?oldid=678362411.
- EGFR_inhibitors isPrimaryTopicOf EGFR_inhibitors.